Pyxis Oncology (PYXS) Tax Provisions (2024 - 2025)
Pyxis Oncology (PYXS) posted quarterly Tax Provisions of $1.4 million for Q4 2025, up 164.05% year-over-year from $524904.4 in Q4 2024, and up 389.75% quarter-over-quarter from $283000.0 in Q2 2025.
Pyxis Oncology (PYXS) Tax Provisions (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Tax Provisions for 2 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Tax Provisions rose 164.05% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at -$495000.0 (changed N/A YoY), while the FY2025 annual figure was $1.4 million, up 164.05% from the prior year.
- Tax Provisions advanced to $1.4 million in Q4 2025 per PYXS's latest filing, from $283000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $1.4 million in Q4 2025 and bottomed at -$2.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.39 Mn |
| Jun 30, 2025 | 283,000.00 |
| Dec 31, 2024 | -2.16 Mn |